Thelansis

Ascites Market Outlook Thelansis’s “Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed experts ...

  Ascites Market Outlook Thelansis’s “Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Ascites Overview Ascites are the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often marking the transition from compensated to decompensated cirrhosis. Approximately 50% of patients with decompensated cirrhosis develop ascites within 10 years, leading to increased mortality due to complications like spontaneous bacterial peritonitis and hepatorenal syndrome. In the United States, cirrhosis is the leading cause of ascites, acc...

  Ascites are the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often marking the transition from compensated to decompensated cirrhosis. Approximately 50% of patients with decompensated cirrhosis develop ascites within 10 years, leading to increased mortality due to complications like spontaneous bacterial peritonitis and hepatorenal syndrome. In the United States, cirrhosis is the leading cause of ascites, accounting for about 80% of cases. Other causes include cancer (10%), heart failure (3%), tuberculosis (2%), dialysis (1%), pancreatic disease (1%), and other factors (2%). Hemorrhagic ascites, occurring in up to 19% of cirrhosis patients, may result from spontaneous causes, with 72% attributed to bloody lymph and 13% to hepatocellular carcinoma. The initial abnormality in cirrhosis-related ascites is portal hypertension, where increased portal pressure and elevated circulating nitric oxide levels lead to vasodilation. As...